Another competition of Alzheimer drugs

A year after Eisai's Riekembi, Lilly launched Kisunla, an anti-Aβ antibody, intensifying competition for Alzheimer's disease drugs.
Surprisingly, Lilly has demonstrated a market development strategy that is strongly focused on insurance benefit companies.
https://miyata-bio.net/column/0000362/